This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Zyflo IV

Chiesi Farmaceutici S.p.A.

Drug Names(s): Zileuton IV (intravenous), Zileuton injection

Description: BioMedTracker has separate drug profiles for the immediate release (IR), controlled release (CR) and intravenous (IV) formulations of Zyflo. Please also see Zyflo IR and Zyflo CR.

Zileuton is an orally active inhibitor of 5-lipoxygenase, the enzyme that catalyzes the formation of leukotrienes from arachidonic acid.

Deal Structure: Critical Therapeutics and Abbott
In December 2003, Critical Therapeutics (CT) acquired an exclusive worldwide license from Abbott to develop, make, use and sell controlled-release and intravenous formulations of zileuton for all clinical indications, except for the treatment of children under age seven and use in cardiovascular and vascular devices. This license included an exclusive sublicense of Abbotts rights in proprietary controlled-release technology originally licensed to Abbott by Jagotec AG, a subsidiary of SkyePharma. In consideration for the license, CT paid Abbott an initial $1.5 million license fee and agreed to make aggregate milestone payments of up to $13.0 million to Abbott upon the achievement of various development and commercialization milestones, including the completion of the technology transfer from Abbott to CT, filing and approval of a product in the United States and specified minimum net sales of licensed products. In addition, CT agreed to pay...See full deal structure in Biomedtracker

Partners: AbbVie Inc.


Zyflo IV News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug